Replay available

OmniAb, Inc. (OABI) Q2 2025 Earnings Call

OmniAb, Inc. (NASDAQ: OABI) Q2 2025 earnings conference call, held 2025-08-06. Replay captured from the company's public earnings webcast.

Wed, August 6, 2025 at 4:30 PMendedReplay
OmniAb, Inc. (OABI) Q2 2025 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Matt Foer

President and CEO, OmniApp

Puneet Sudha

Analyst, Lirina

Jackson Schrader

Analyst, Craig Howland Capital Group

Steven Willie

Analyst, Stifel

Eric Carter

Analyst, RBC Capital Markets

Replay transcript excerpt

results. These forward-looking statements are qualified by the cautionary statements contained in today's press release and our SEC filings. Importantly, this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast today, August 6, 2025. Except as required by law, OMNIEV undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this call. Joining me on the call today is Matt Foer, OmniApp's President and CEO. And during today's call, we'll provide highlights on the company's business and operations, partner and technology updates, as well as our recent financial results and outlook. And at the conclusion of the prepared remarks, we'll open the call to questions. And with that, let me turn the call over to Matt. Thanks, Kurt. Good afternoon, everyone, and thanks for joining us today on our Q2 call. I'll start now with slide number four. As I mentioned on our last call, we started the year with strong deal flow, and it continued in the second quarter with a number of new partners added in the first half of the year, setting a pace for one of our strongest years yet. We continue to see a robust pace and quality of deals, and we think this is a testament to our differentiated technology platform, which continues to evolve and expand, and to our team's relentless pursuit of innovation that leverages our unique vantage point in the industry. Our partners are actively advancing programs into human trials with the start of a new clinical stage program during the second quarter and several others that are progressing through development. And on the third highlight here on slide four, the recent launch of our Exploration Partner Access program has been...

More from Omniab, Inc.